Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Feb;28(1):279-280.
doi: 10.1007/s10029-023-02822-y. Epub 2023 Jun 23.

Comment to: Comparison of mechanical properties and host tissue response to OviTex™ and Strattice™ surgical meshes

S J Pacella  1 , R Nazerali  2
Affiliations
Comment

Comment to: Comparison of mechanical properties and host tissue response to OviTex™ and Strattice™ surgical meshes

S J Pacella et al. Hernia. 2024 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Salvatore J. Pacella is a consultant for Mentor Worldwide and TELABio Inc. Rahim Nazerali is a consultant for Mentor Worldwide, the Musculoskeletal Transplant Foundation and TELABio Inc.

Comment in

Comment on

References

    1. Lombardi J, et al. Comparison of mechanical properties and host tissue response to OviTex and Strattice surgical meshes. Hernia. 2023 doi: 10.1007/s10029-023-02769-0. - DOI - PMC - PubMed
    1. Sivaraj D, et al. Reinforced biologic mesh reduces postoperative complications compared to biologic mesh after ventral hernia repair. Plast Reconstr Surg Glob Open. 2022;10(2):e4083. doi: 10.1097/GOX.0000000000004083. - DOI - PMC - PubMed
    1. Goetz M, Jurczyk M, Junger H, et al. Semiresorbable biologic hybrid meshes for ventral abdominal hernia repair in potentially contaminated settings: lower risk of recurrence. Updates Surg. 2022;74:1995–2001. doi: 10.1007/s13304-022-01378-3. - DOI - PMC - PubMed
    1. Parker MJ, Kim RC, Barrio M, Socas J, Reed LR, Nakeeb A, House MG, Ceppa EP. A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients. Surg Endosc. 2021;35(9):5173–5178. doi: 10.1007/s00464-020-08009-1. - DOI - PubMed
    1. DeNoto G, 3rd, Ceppa EP, Pacella SJ, Sawyer M, Slayden G, Takata M, Tuma G, Yunis J. 24-month results of the BRAVO study: a prospective, multi-center study evaluating the clinical outcomes of a ventral hernia cohort treated with OviTex® 1S permanent reinforced tissue matrix. Ann Med Surg (Lond) 2022;27(83):104745. - PMC - PubMed

LinkOut - more resources